10-K: Lixte Biotech Reports Wider Loss, Acquires Proton Therapy Unit

Lixte Biotechnology Holdings, Inc. reported a significantly wider net loss in 2025, driven by increased administrative costs and digital asset losses, while strategically acquiring a proton therapy system and navigating clinical trial developments.

Summary

• Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage biopharmaceutical and proton cancer therapy company.
• The company reported a net loss of $6,009,520 for the year ended December 31, 2025, compared to $3,585,965 in 2024.
• Cash used in operations was $3,070,618 in 2025, slightly down from $3,164,536 in 2024.
• Cash reserves increased to $5,106,872 at year-end 2025, up from $1,038,952 in 2024, primarily due to equity financings.
• Lixte acquired an 80% ownership interest in Liora Technologies Europe Ltd. on November 21, 2025, gaining the LiGHT proton therapy system, which is a non-clinical prototype requiring $2 million and 24 months to recommission.
• The acquisition of Liora involved a total consideration of $5,189,966 for the 80% interest, including cash, digital assets (Bitcoin and Ethereum), and common stock.
• Lixte assumed a $5 million deferred payment to AVO, contingent on the LiGHT system obtaining regulatory certification and Liora's revenue exceeding $30 million.
• Research and development costs decreased significantly to $254,919 in 2025 from $726,232 in 2024, partly due to the termination of the City of Hope clinical trial and reduced financial commitment to the GEIS trial.
• General and administrative costs increased to $4,852,702 in 2025 from $2,846,557 in 2024, largely due to higher stock-based compensation and consulting fees.
• A realized loss of $904,394 on digital assets was recorded in 2025 due to their transfer as consideration for the Liora acquisition.
• The company regained compliance with Nasdaq's $2.5 million stockholders' equity requirement by July 15, 2025, following private placements and direct offerings, but remains under a Panel Monitor until July 15, 2026.
• The Netherlands Cancer Institute (NKI) clinical trial for metastatic colorectal cancer (LB-100 + atezolizumab) was paused due to two Serious Adverse Events (SAEs), including one patient death, but reopened for enrollment in Q1 2026 after IRB questions were addressed.
• The GEIS clinical trial for advanced soft tissue sarcoma (LB-100 + doxorubicin) completed its Phase 1b recruitment in Q3 2024, with preliminary efficacy data expected in Q1 2026; the Phase 2 portion will not proceed due to Lixte's reduced financial obligation of $3,095,000.
• The MD Anderson Cancer Center clinical trial for ovarian clear cell carcinoma (LB-100 + dostarlimab) expanded enrollment from 21 to 42 patients in December 2025, with the first 21 patients enrolled in Q4 2025 and patient 22 expected in Q1 2026.
• Lixte settled a legal claim from FX Group Inc. for $100,000 in January 2026, accruing the expense as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution. While the company successfully raised capital and diversified into proton therapy, significant financial losses, a 'going concern' warning, and clinical trial setbacks (SAEs, terminations, delays) present substantial risks to its operational stability and future prospects.

Positives

• Successfully raised $10,311,000 in gross proceeds from securities offerings in 2025, significantly increasing cash reserves and working capital.
• Regained compliance with Nasdaq's minimum stockholders' equity requirement by July 15, 2025, ensuring continued listing.
• Strategic acquisition of Liora Technologies Europe Ltd. and its LiGHT proton therapy system diversifies the company into the advanced cancer treatment technology sector.
• Expansion of the MD Anderson clinical trial for ovarian clear cell carcinoma from 21 to 42 patients, indicating continued progress and collaboration with GSK and Northwestern University.
• Resolution of the IRB hold on the Netherlands Cancer Institute colorectal cancer study, allowing enrollment to resume in Q1 2026.
• Reduced financial obligation for the GEIS advanced soft tissue sarcoma trial by $3,095,000, optimizing capital allocation.
• Continued expansion of the patent portfolio for LB-100, including combination therapies with checkpoint inhibitors and other investigational compounds, with projected expirations extending to 2043.

Negatives

• Reported a significantly wider net loss of $6,009,520 in 2025, compared to $3,585,965 in 2024.
• General and administrative costs increased substantially by 70% to $4,852,702 in 2025, primarily due to higher stock-based compensation and consulting fees.
• Incurred a realized loss of $904,394 on digital assets in 2025.
• The company's independent registered public accounting firm expressed substantial doubt about its ability to continue as a going concern.
• Experienced Serious Adverse Events (SAEs) in the Netherlands Cancer Institute colorectal cancer study, including one patient death, leading to a temporary clinical hold.
• Terminated the City of Hope clinical trial for small cell lung cancer due to lack of patient accrual, indicating challenges in trial execution.
• The LiGHT proton therapy system is a non-clinical prototype requiring an estimated $2 million and 24 months to recommission, with no immediate clinical operability or revenue generation.
• The company has no recurring source of revenue and does not expect to generate sustainable operating revenues for several years, if ever.

Risks

• Substantial doubt about the ability to continue as a going concern due to no recurring revenue and negative operating cash flows.
• Need for significant additional financing by mid-2026 to fund operations and complete product development, with no committed source of capital.
• Uncertainty of success in early-stage research and development, with potential for product candidates to be unsafe or ineffective.
• Difficulty in enrolling patients in clinical trials, which could delay or prevent trial completion and regulatory approval.
• Unpredictable outcomes of clinical trials, where preclinical or earlier phase results may not be predictive of later success.
• Potential for undesirable side effects or other properties of product candidates to delay or prevent regulatory approval or limit commercialization.
• Risk of clinical trials being placed on hold or terminated due to Serious Adverse Events (SAEs) related to drug candidates.
• Dependence on timely regulatory approval for product candidates, which is a lengthy, expensive, and uncertain process.
• Risks associated with operating in foreign countries, including differing regulatory requirements, economic instability, and foreign currency fluctuations.
• Dependence on third parties (CROs, CMOs, collaborators) for clinical trials and manufacturing, with risks of non-performance or delays.
• Challenges in protecting intellectual property rights, including obtaining new patents, defending existing ones, and potential infringement claims from third parties.
• Competition from major pharmaceutical companies and specialized biotechnology firms with greater resources and more effective technologies.
• Business interruptions from natural disasters, system failures, or geopolitical events, which could delay operations and R&D programs.
• Challenges in managing future organizational growth, including hiring and retaining qualified personnel.
• Potential conflicts of interest arising from the CEO's simultaneous roles in other companies.
• Impact of unstable market and economic conditions on financing and business operations.
• Provisions in certain warrants that could discourage change-in-control transactions due to potential cash redemption requirements.
• Potential for substantial dilution from future sales and issuances of common stock.
• Risk of securities class action litigation due to stock price volatility.
• Anti-takeover effects from corporate governance provisions that could discourage acquisitions.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances clinical development and seeks regulatory approvals. It anticipates needing to raise additional capital by mid-2026 to fund operations and clinical trial commitments through 2027. The long-term objective for the biopharmaceutical segment is to secure strategic partnerships or licensing agreements, while the Liora LiGHT system is positioned as a functional prototype for future licensing and commercialization, requiring significant investment for clinical operability.

Management Comments

• "The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date hereof, but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning."
• "The Company believes that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for clinical use."
• "The Companys longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies with major programs in cancer."
• "The Companys strategy for the LiGHT system is to position it as a functional prototype asset (rather than a turnkey clinical system), valued primarily for its intellectual property, accelerator hardware configuration, and accumulated engineering work, without immediate clinical operability. It will be saleable as a functional unlicensed prototype to be copied and licensed at locations closer to large patient populations."
• "Management is actively evaluating and pursuing additional financing alternatives, including equity and debt financings and potential strategic transactions."
• "The investigators have completed the IRB review in Q4 2025 and the trial is open again for enrolment Q1 2026."

Industry Context

StockSavvy.ai notes that Lixte's dual focus on clinical-stage biopharmaceuticals and advanced proton cancer therapy positions it in two high-growth, high-risk segments of the oncology market. The biopharmaceutical industry is characterized by intense competition, lengthy and costly development cycles, and high regulatory hurdles, where success hinges on demonstrating superior efficacy and safety. The proton therapy market, while developing, is dominated by established players like Varian, IBA, and Hitachi, making Lixte's entry with the LiGHT system a disruptive but capital-intensive endeavor. The emphasis on combination therapies and novel mechanisms like 'activation lethality' for LB-100 aligns with broader industry trends seeking to enhance existing treatments and address unmet medical needs. However, the significant capital requirements and the 'going concern' warning highlight the inherent financial challenges faced by early-stage companies in these sectors.

Comparison to Industry Standards

• Lixte's LB-100, as a protein phosphatase 2A inhibitor, represents a novel approach in cancer biology ('activation lethality'), contrasting with most current cancer therapies that aim to inhibit oncogenic signaling. This positions it uniquely against standard chemotherapy and immunotherapy agents.
• The LiGHT System, as the first Linac-based proton therapy system, offers potential advantages over existing cyclotron technologies used by competitors like IBA Worldwide, Varian Medical Systems, Hitachi, Mevion Medical Systems, ProNova Solutions, P-Cure, and Sumitomo Heavy Industries, particularly in terms of electronic beam control, reduced unwanted radiation, smaller footprint, and FLASH therapy compatibility. However, it is currently a non-clinical prototype, whereas competitors offer commercially available, clinically certified systems.
• The reported median progression-free survival (PFS) assumption of 4.5 months for doxorubicin alone in advanced soft tissue sarcomas (ASTS) and an alternative median PFS of 7.5 months with LB-100 plus doxorubicin in the GEIS trial suggests a targeted improvement of 66% in PFS, which, if achieved, would be a significant clinical benefit compared to the 40-year standard of care.
• The company's reliance on stock-based compensation for a substantial portion of employee and consultant compensation is common for early-stage biotech firms with limited cash flow, but it can lead to significant dilution for shareholders compared to more established companies with robust cash-based compensation structures.

Management Changes

Corporate Governance

Legal Proceedings

• On January 22, 2026, the company entered into a settlement agreement to pay $100,000 to FX Group Inc. and related parties to resolve a demand for consulting fees related to capital offerings completed in June and July 2025. An accrual of $100,000 was recorded as of December 31, 2025.

Related Party Transactions

• Geordan Pursglove, CEO, had his annual salary increased from $240,000 to $360,000 effective January 1, 2026.
• Peter Stazzone, CFO, was appointed with an annual salary of $150,000.
• Bastiaan van der Baan, CSO, received $174,000 in 2025. His employment agreement was amended, and he resigned as President and from the Board but remained CSO.
• Robert N. Weingarten, former VP and CFO, received $116,667 in 2025 before his resignation on September 1, 2025.
• Dr. Jan H.M. Schellens, former CMO, received $67,494 in 2025 before his resignation on July 31, 2025.
• Dr. Ren Bernards, former director, received cash compensation for board services until March 31, 2025, and resigned from the board on August 18, 2025, to become Chairman of the Scientific Advisory Board.
• Total cash-based related party costs were $817,325 in 2025, and stock-based related party costs were $1,388,322 in 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future equity financings, as well as potential reduction in value from warrant provisions that could require cash settlement in a change-in-control. The 'going concern' warning indicates high investment risk. However, the acquisition of Liora and progress in clinical trials offer potential long-term value if successful.
• **Employees/Consultants**: Key personnel changes, including new CEO and CFO appointments, and the resignation of CMO and other directors, indicate a shift in leadership. The increase in stock-based compensation suggests continued reliance on equity incentives for retention. The company's ability to attract and retain talent is critical for its R&D programs.
• **Customers (future)**: The development of LB-100 and the LiGHT proton therapy system aims to provide novel cancer treatments, potentially offering improved outcomes for patients with ovarian clear cell carcinoma, metastatic colorectal cancer, and soft tissue sarcoma. However, clinical trial setbacks and the non-clinical status of LiGHT mean these benefits are not yet realized.
• **Suppliers/Creditors**: The 'going concern' warning and reliance on equity financing pose risks regarding the company's ability to meet future financial obligations. The settlement of the FX Group Inc. claim demonstrates the company's commitment to resolving disputes, but also highlights potential liabilities.

Next Steps

• Complete recommissioning and updating of the LiGHT proton therapy system over the next 24 months, requiring approximately $2 million in expenditure.
• Obtain regulatory clearance for the LiGHT system to become operational for clinical use.
• Continue patient enrollment in the Netherlands Cancer Institute (NKI) colorectal cancer study, which reopened in Q1 2026.
• Expect data on toxicity and preliminary efficacy from the GEIS advanced soft tissue sarcoma Phase 1b clinical trial during Q1 2026.
• Close the GEIS advanced soft tissue sarcoma trial after completion of the first phase in Q1 2026, as the Phase 2 portion will not proceed.
• Enroll patient 22 in the MD Anderson ovarian clear cell carcinoma trial in Q1 2026, continuing the expanded enrollment to 42 patients.
• Actively evaluate and pursue additional financing alternatives, including equity and debt financings and potential strategic transactions, to fund operations beyond mid-2026.
• Prepare a detailed response to the NKI IRB regarding the Serious Adverse Events in the colorectal cancer study, including an updated safety overview of LB-100.
• Monitor Nasdaq compliance under the Panel Monitor through July 15, 2026.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, a critical red flag for investors. Despite recent capital raises, the significant increase in net loss, coupled with a substantial realized loss on digital assets, indicates deteriorating financial health. Clinical trial setbacks, including a patient death and trial terminations, introduce considerable uncertainty and risk to its core drug development pipeline. The acquisition of the proton therapy system, while strategic, is a long-term, capital-intensive project with no immediate revenue, adding to the financial burden. The stock remains highly speculative, with a high risk of further dilution and potential delisting if Nasdaq compliance issues re-emerge. A seasoned investor would likely view these factors as overwhelmingly negative, warranting a 'strong sell' recommendation.

Keywords

Biopharmaceutical, Cancer Therapy, Proton Therapy, LB-100, Clinical Trials, Ovarian Clear Cell Carcinoma, Metastatic Colorectal Cancer, Advanced Soft Tissue Sarcoma, LiGHT System, Protein Phosphatase Inhibitor, Immunotherapy, Oncology, SEC Filing, 10-K, Nasdaq Compliance, Going Concern, Intellectual Property, Drug Development, Biotech Investment